Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.46 |
| ▸ | CDK9 | P50750 | 4/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | PIP5K1C | O60331 | 6/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIP5K1B | O14986 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PIP5K1A | Q99755 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285782 | 0.90 | DYRK1A (0.46) | IRAK4CCNT1CDK9MAPK8MAPK10 | |
| SCHEMBL10243993 | 0.88 | PIP5K1C (0.53) | CDK9MAPK8MAPK10MAPK14PIP5K1C | |
| SCHEMBL1949675 | 0.86 | CCNT1 (0.60) | CCNT1CDK9 | |
| SCHEMBL12565545 | 0.85 | IRAK4 (0.50) | IRAK4CCNT1CDK9MAPK8MAPK10 | |
| SCHEMBL1946510 | 0.85 | CDK9 (0.59) | IRAK4CCNT1CDK9MAPK8MAPK10 | |
| SCHEMBL12563382 | 0.84 | IRAK4 (0.49) | IRAK4CCNT1CDK9MAPK8MAPK10 | |
| SCHEMBL12564527 | 0.79 | CCNT1 (0.51) | IRAK4CCNT1CDK9MAPK14PIP5K1C | |
| SCHEMBL12566389 | 0.79 | CCNT1 (0.51) | IRAK4CCNT1CDK9MAPK14PIP5K1C | |
| SCHEMBL10285338 | 0.78 | CCNT1 (0.60) | CCNT1CDK9 | |
| SCHEMBL10242753 | 0.77 | CDK9 (0.51) | CCNT1CDK9PIP5K1CPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101064-A1 | N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | IRAK4 1446/4885CCNT1 47/4885CDK9 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.